Fipharm Group Competitors

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma’s therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 19 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas. Along with a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and Europe, Luye Pharma has reached high-level international standards in advanced drug delivery technologies including microspheres, liposomes and transdermal drug delivery systems, as well as actively making strategic developments in the fields of innovative new compounds and antibodies, gene & cell therapies and smart formulations. Luye Pharma is developing a global supply chain of 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the 4 largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and central nervous system, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets.

齐鲁制药集团主要从事肿瘤、心脑血管、感染、精神系统、神经系统、眼科疾病的制剂及原料药的研制、生产与销售。下设13家子公司，员工23000余人。2019年度，实现销售收入251亿元，上交税金23亿元，实现出口6.15亿美元；位列2018年度中国医药工业百强榜第8位。 齐鲁制药始终坚持创新驱动战略，建立了中美联动五大研发平台，专职研发人员2000余人。每年销售收入的6%以上投入研发。在研创新药物项目合计50余项。在精准靶向治疗、免疫治疗、细胞治疗和新型给药系统等领域全面布局，持续抢占国际药物研发新高地。